业绩承压,石药集团创新药故事能否兑现?

投资时间
06 Jun

石药集团第一季度总收入约70.15亿元,同比下降21.9%;归母净利润同比减少8.4%,降至14.78亿元投资时间网、标点财经研究员 习羽业绩承压之下,如何重振市场信心成为石药集团(01093.HK)亟待破解的课题。近日,石药集团发布公告称,其自主研发的JMT101获国家药监局药品审评中心授予突破性治疗认定,该药物拟用于治疗特定基因型晚期结直肠癌,为二线及以上治疗失败的患者带来新希望。而在这一消息...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10